Loading quotes...
Forecast
| Buy |
2 |
| Hold |
0 |
| Sell |
0 |
Discussions in the community
There is no discussion about this asset yet.
Start discussionNews Go to news feed
InMed Pharmaceuticals meets NASDAQ minimum bid-price requirement again
NASDAQ said InMed Pharmaceuticals has met the listing requirement after the closing price of its common stock was at or above $1.00 for ten consecutive trading days from May 19 through last Monday. The exchange has closed the matter; the stock currently trades at $1.56 and, despite a 50% year-to-date increase, remains well below the 52-week high of $5.50. InMed has a market capitalization of $6.96 million and is developing small-molecule drug candidates targeting CB1/CB2 receptors with programs for Alzheimer’s, eye diseases and dermatology. » More on de.investing.com
InMed Pharmaceuticals files prospectus supplement for at-the-market offering
InMed Pharmaceuticals has filed a prospectus supplement and the related prospectus with the U.S. securities regulator SEC for the sale of common shares under an existing at-the-market agreement with H.C. Wainwright & Co. The filing relies on the S-3 shelf registration that the SEC declared effective on March 30, 2026. The supplement includes a legal opinion from Norton Rose Fulbright Canada LLP on the validity of the offered securities. » More on de.investing.com
InMed Pharmaceuticals faces delisting after falling below Nasdaq minimum bid price
InMed Pharmaceuticals received a notice from Nasdaq because the stock’s closing price was below $1.00 for 30 consecutive trading days between Feb. 11 and Mar. 26, 2026. The shares currently trade at $0.66 with a market capitalization of $2.59 million; InMed has 180 calendar days to cure the deficiency by achieving a closing price of at least $1.00 for ten consecutive trading days. If the company does not comply, a one-time extension is possible; otherwise delisting is threatened, with a possible appeal to the Nasdaq Hearings Panel. InMed is evaluating options such as a reverse stock split and will monitor the share price. » More on de.investing.com
InMed Pharmaceuticals reports quarterly loss of $0.43 per share and moderate revenue increase
InMed Pharmaceuticals released results for the quarter ended June 30, 2025: loss per share was $0.43 compared with -$3.80 in the year-ago quarter. Quarterly revenue was $1.3 million (+1.56% year on year). For the full year, loss per share narrowed to $8.36 (prior year -$20.20) on revenue of $4.94 million (+7.39% year on year). » More on finanzen.net
InMed Pharmaceuticals sets date and record date for 2025 annual general meeting
InMed Pharmaceuticals announced the date, record date and organizational details for its 2025 annual general meeting and filed the information on SEDAR and in a Form 8‑K with the SEC. The company gave no information on agenda items or proposals. It is registered in British Columbia, headquartered in Vancouver; its common shares trade on NASDAQ under the ticker INM; market capitalization is about 4.31 million USD and the stock is down more than 52% year-to-date. » More on de.investing.com
Financials
| (EUR) | September 2026 | YoY |
|---|---|---|
| Revenue | 0 | 100.00% |
| Gross profit | -195.14k | 156.80% |
| Net profit | -2.06m | 39.83% |
| EBITDA | -1.58m | 18.09% |
Fundamentals
| Metric | Value |
|---|---|
Market capitalization | €7.77m |
Number of shares | 549.37k |
52-week high/low | €21.19 - €5.23 |
| Dividends | No |
Beta | 0.99 |
P/E ratio | -0.60 |
PEG ratio | -0.01 |
P/B ratio | -8.48 |
P/S ratio | 0.00 |
Company profile
InMed Pharmaceuticals Inc., a clinical stage pharmaceutical company, researches and develops cannabinoid-based therapies. The company's lead product is INM-755, a cannabinol topical cream, which is in a second Phase I clinical trials for the treatment of epidermolysis bullosa. The company is also involved in developing INM-088, which is in preclinical studies for the treatment of glaucoma; and INM-405 for the treatment of pain. In addition, it engages in the development of cannabinoid-based treatments for various diseases, including dermatology and ocular diseases. Further, the company works on IND-enabling pharmacology and preclinical toxicology studies; and IntegraSyn, an integrated biosynthesis-based manufacturing approach, for synthesizing pharmaceutical-grade cannabinoids. It has a research collaboration agreement with BayMedica Inc. for the manufacturing and testing of novel cannabinoid therapeutics. The company was formerly known as Cannabis Technologies Inc. and changed its name to InMed Pharmaceuticals Inc. in October 2014. InMed Pharmaceuticals Inc. was incorporated in 1981 and is headquartered in Vancouver, Canada.
| Name | InMed Pharmaceuticals |
| CEO | Eric A. Adams Chem. |
| Headquarters | Vancouver,
bc Canada |
| Website | |
| Sector | Materials |
| Industry | Chemicals |
| IPO | 05/05/2014 |
| Employees | 6 |
Ticker symbols
| Exchange | Symbol |
|---|---|
NASDAQ | INM |
Frankfurt | MWG.F |